Theories of desistance from crime have emphasized social processes like involvement in adult social bonds or prosocial social relationships to the deliberate neglect of individual subjective processes such as one’s identity. More recent theories, however, have stressed the role of identity and human agency in the desistance process. An important set of questions is whether identity theory adds anything to existing theories, and whether there is empirical evidence to suggest that such subjective processes are important. In this article, we provide an empirical assessment of individual subjective considerations in desistance by looking at the relationship between “good identities,” intentional self-change, and desistance using survival time data from a sample of serious drug-troubled adult offenders released from prison whose arrest records are followed for almost a 20-year period. The implications of our findings for all brands of criminal desistance theory are discussed.

Abstract We report the first case of a pediatric patient with glioblastoma (GBM; WHO grade IV astrocytoma) successfully treated with tumor treating fields (TTF). The patient was diagnosed with GBM when 13 years of age and progressed through surgical resection, radiotherapy and chemotherapy. Discrete tumor growth visualized on MRI with stable neurological examination was monitored for 6 months with subsequent stable disease observed radiographically and clinically for 7 months while adherent to Optune® (TTF). TTF thereby played a role in forestalling recurrent GBM growth in this young woman for 7 months without significant adverse effects. We propose that TTF therapy is a potential valuable treatment in this small, but sick, patient population.

We report the first case of a pediatric patient with glioblastoma (GBM; WHO grade IV astrocytoma) successfully treated with tumor treating fields (TTF). The patient was diagnosed with GBM when 13 years of age and progressed through surgical resection, radiotherapy and chemotherapy. Discrete tumor growth visualized on MRI with stable neurological examination was monitored for 6 months with subsequent stable disease observed radiographically and clinically for 7 months while adherent to Optune^® (TTF). TTF thereby played a role in forestalling recurrent GBM growth in this young woman for 7 months without significant adverse effects. We propose that TTF therapy is a potential valuable treatment in this small, but sick, patient population.

Extant theoretical work on desistance from crime has emphasized social processes such as involvement in adult social bonds or pro-social relationships, with very little attention given to individual subjective processes such as one’s identity. The desistance theories of Sampson and Laub and Giordano seem to have reached the point of consensual acceptance in the field. Theoretical work within the past 5 years, however, have begun to stress the role of identity and human agency in the desistance process including Paternoster and Bushway’s (2009) identity theory of desistance (ITD), which offers a rational choice perspective on how offenders quit crime. This paper provides a critical theoretical assessment of both the age-graded informal social control theory of desistance and the theory of cognitive and emotional transformation, illuminating the critical theoretical omissions and empirical inconsistencies in each. We suggest that the apparent consensus in the criminological literature regarding desistance theory may be premature and highlight the advantages provided by theories that emphasize the internal cognitive dimensions of change including the ITD.

Using a mixed-race sample of male and female drug-involved offenders who were released from prison in the early 1990s and re-interviewed in 2009 through 2011, this article represents perhaps the first attempt to determine the utility of the identity theory of desistance (ITD) in explaining desistance in a contemporary cohort of adult drug-involved offenders. Supporting the ITD, interview narratives revealed that the vast majority of offenders who successfully desisted from crime and substance misuse had first transformed their offender identity into a non-offender identity. Although partnership and employment did not appear to be significant turning points per se for the majority of our respondents, rekindling relationships with extended family and finding living-wage employment did serve to solidify new prosocial identities once the transformation had occurred.

NovoTTF treatment is an FDA approved treatment strategy for recurrent Glioblastoma multiforme (GBM) management which employs alternating electric fields to the region of the malignant tumor through probes on the patient's head which is thought to improve time to disease progression of GBM via cell cycle mitosis disruption. A patient is described with recurrent GBM who had disease progression following initial standard surgical treatment and concomitant chemo-radiotherapy and was found to have sarcomatous transformation after initiation of NovoTTF-100A electrical device therapy with bevacizumab. Upon tumor progression, less than two years after initial diagnosis, the patient underwent surgical resection which revealed transformation from a GFAP-positive WHO grade IV astrocytoma into a GFAP-negative, reticulin-positive sarcoma with rhabdomyoid features following histopathological evaluation. The possibility of a causal connection between the NovoTTF therapy and sarcomatous transformation needs to be further evaluated. No such case of sarcoma progression in the CNS following chemo-radiotherapy and/or electrical current treatment for Glioblastoma multiforme has been reported in the literature.

Optune^® treatment is a US FDA-approved treatment for glioblastoma (GBM) that employs alternating electric fields. Tumor treating field (TTF) therapy can exert its effects on GBM via cell cycle mitosis disruption and cytokinesis. We describe a patient with recurrent GBM who had disease progression following standard surgical treatment and concomitant chemoradiotherapy, and was found to have sarcomatous transformation after initiation of TTF therapy with bevacizumab. Upon tumor progression, repeat surgical resection revealed transformation into a GFAP-negative, reticulin-positive sarcoma with rhabdomyoid features. The possibility of a causal connection between TTF therapy and sarcomatous transformation needs to be further evaluated. No such case of apparent sarcoma formation in the CNS following chemoradiotherapy and/or TTF treatment for GBM has been reported.